Financial Comparison: Whitehawk Therapeutics (NASDAQ:WHWK) vs. BetterLife Pharma (OTCMKTS:PVOTF)

Whitehawk Therapeutics (NASDAQ:WHWK) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Whitehawk Therapeutics and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-68.32%	-63.21%
BetterLife Pharma	N/A	-205.15%	-147.23%

Valuation & Earnings

This table compares Whitehawk Therapeutics and BetterLife Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	4.34	-$63.69 million	$0.14	17.07
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

BetterLife Pharma has lower revenue, but higher earnings than Whitehawk Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Whitehawk Therapeutics and BetterLife Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
BetterLife Pharma	0	0	0	0	0.00

Given BetterLife Pharma’s higher possible upside, analysts plainly believe BetterLife Pharma is more favorable than Whitehawk Therapeutics.

Summary

Whitehawk Therapeutics beats BetterLife Pharma on 8 of the 10 factors compared between the two stocks.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.